The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

Launched by VANDERBILT-INGRAM CANCER CENTER · Nov 20, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository, is studying a condition known as clonal hematopoiesis (CH). CH happens when there are mutations in a person's blood stem cells, which are crucial for producing blood cells. These mutations are more common as people age and can lead to a higher risk of certain cancers and heart disease. The researchers want to better understand how CH is connected to these health issues and to gather information that could help improve patient care in the future.

To participate in this study, you must be at least 18 years old and able to give consent. You may be eligible if you have certain blood-related conditions or are at higher risk for clonal hematopoiesis due to existing health problems, like solid tumors or heart disease. Participants can expect to provide health information and may be asked to undergo tests to help researchers learn more about how CH affects overall health. It's important to note that individuals currently diagnosed with active blood cancers, like leukemia, cannot join the study. This research is a valuable opportunity to contribute to our understanding of clonal hematopoiesis and its links to other serious health conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient greater than or equal to 18 years old at time of consent
• • Able to provide informed consent
• • Idiopathic cytopenia (ICUS) or idiopathic cytoses (elevated blood counts without disease or explanation); clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or individuals at higher risk for clonal hematopoiesis (ex. patients with known diagnosis of solid tumors or cardiovascular disease)
• Exclusion Criteria:
• • Unable to provide consent
• • Diagnosis of active hematologic malignancy. For example, a diagnosis of CMML, AML, MDS, MPN; History of hematologic malignancy is NOT exclusionary if in complete remission (e.g. previous myeloma or lymphoma)